Eyenuk, a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, has received U.S. Food and Drug Administration (FDA) clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras.
The regulatory clearance of the EyeArt v2.2.0 system makes it the first and only AI system that is FDA-cleared for use with multiple retinal cameras by different manufacturers. This clearance builds upon the EyeArt system’s launch in August 2020 as the first and only AI technology to be cleared by the FDA to detect both more than mild and vision-threatening DR. In the European Union, the EyeArt system is the first and only AI system approved under MDR Class IIb to detect DR, age-related macular degeneration, and glaucomatous optic nerve damage, in a single test.
Since its launch in global markets, the EyeArt system has been used by hundreds of clinics to enable safe and reliable eye screening for over 230,000 patients with diabetes and counting.
Also Read: Qardio Introduces Revolutionary Livestream ECG Monitoring and Advances Healthcare
“I am particularly thrilled about this clearance as it showcases our extraordinary commitment towards our mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases,” said Kaushal Solanki, PhD, Founder and CEO of Eyenuk. “The EyeArt system can now be used with multiple camera models in the U.S., which significantly expands access for patients who can be screened in their primary care doctor’s office for preventable blindness due to diabetes.”
This latest FDA clearance for the EyeArt v2.2.0 system is based on clinical data from a prospective multi-center clinical trial (ClinicalTrials.gov ID NCT04984200) that demonstrated exceptional performance for the Topcon NW400 cameras, as summarized below.
- 94.4% sensitivity and 91.1% specificity for more than mild DR detection, and
- 96.8% sensitivity and 91.6% specificity for vision-threatening DR detection
Additionally, with this clearance, the EyeArt system gets an upgraded image quality assessment module and Eyenuk’s proprietary Real-Time Image Quality Feedback solution. These enhancements improve the EyeArt system’s usability, achieving the best-in-class gradability (i.e., percentage of patients with conclusive reports) without the need for dilation.
In the clinical trial, for all camera models (Canon CR-2 AF, Canon CR-2 Plus AF, and Topcon NW400) conclusive EyeArt results were available for 90.4% of cases without needing dilation and for 99% of cases when a small fraction was dilated after the quality feedback solution recommended dilation.
SOURCE: PRNewswire